BridgeMD
Compares treatment options for Non-Small Cell Lung Cancer
Official title Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov ID: NCT06236438
What this study is testing
What is Livmoniplimab?
Livmoniplimab is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for non-small cell lung cancer.
Also referred to as ABBV-151.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab plus chemotherapy versus pembrolizumab plus chemotherapy in participants with untreated metastatic non-squamous non-small cell lung cancer.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Diagnosis of histologically or cytologically confirmed metastatic nonsquamous non-small cell lung cancer (NSCLC) with no known epidermal growth...
- Must have at least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST) v1.1 as determined by the local site...
- Life expectancy of at least 3 months and adequate organ function.
You likely can't join if
- \- Received prior systemic therapy for the treatment of metastatic NSCLC.
The study team makes the final eligibility decision.
Where it's taking place
- La Jolla, California, United States
- Pembroke Pines, Florida, United States
- Winter Haven, Florida, United States
- Athens, Georgia, United States
- Chicago, Illinois, United States
- Westwood, Kansas, United States
- Lexington, Kentucky, United States
- Grand Rapids, Michigan, United States
- St Louis, Missouri, United States
- Stony Brook, New York, United States
- Greensboro, North Carolina, United States
- Cincinnati, Ohio, United States
- Sayre, Pennsylvania, United States
- El Paso, Texas, United States
- Houston, Texas, United States
- Plano, Texas, United States
- San Antonio, Texas, United States
- The Woodlands, Texas, United States
- Olympia, Washington, United States
- Garran, Australian Capital Territory, Australia
+ 37 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include La Jolla, California, United States; Pembroke Pines, Florida, United States; Winter Haven, Florida, United States; Athens, Georgia, United States; Chicago, Illinois, United States; Westwood, Kansas, United States and 51 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.